Dihydrotestosterone (DHT) treatment significantly increased PEX10 expression at the mRNA and protein levels in prostate cancer cells, including C4-2 and LNCaP cells, while enzalutamide treatment decreased PEX10 expression, which is consistent with the changes in KLK3 (Fig. 5C–E) and our previous conclusions. This evidence concerns the gene PEX10 and prostate carcinoma.